Introducing SMi's 6th annual conference on Pharmaceutical Freeze Drying Technology this June 2018

SMi Group13 - 14 June 2018, London, UK.
Although an old process, pharmaceutical freeze drying is ever evolving with new trends and approaches being used for pharmaceutical formulation. In it's 6th year, the conference will cover the most recent advances in Freeze drying technology and discuss the latest ideas in the industry. It is the perfect platform to strengthen knowledge in key principles such as PAT and QbD, whilst staying at the forefront of technological breakthroughs to adapt to growing manufacturing demands.

Gathering a room of Senior Scientists and Heads of Pharmaceutical Engineering, the 6th annual show provides an ideal forum to discuss the latest advancements in pharmaceutical lyophilisation, welcoming regulatory guidance from the NIBSC-MHRA and expertise from the likes of Sanofi, Boehringer Ingelheim, Janssen, GSK and more.

Network & Benefit From Industry Experts:

  • [CHAIR] SuneKlint Anderson, Principal Scientist, Janssen
  • Paul Matejtschuk, Principal Scientist, NIBSC - MHRA
  • Mostafa Nakach, Head of Pharmaceutical Engineering, Sanofi
  • ErwanBourles, Expert Scientist, Head Filling Drying Device, GlaxoSmithKline
  • MiguelaVieru, Senior Scientist, Janssen
  • Eric Munson, Patrick Deluca Endowed Professor of Pharmaceutical Technology, University of Kentucky
  • Patrick Garidel, Bioprocess and Pharmaceutical Development Biologicals, Boehringer Ingelheim
  • Daryl Williams, Reader in Particle Science, Imperial College London

Featured Highlights this June:

  • Discuss the use of old and new methods in terms of the optimisation of freeze drying cycles
  • Learn about case studies which delve into the processes through which cycles can be refined to the utmost efficiency
  • Hear about a new PAT for freeze drying cycle development through vial impedance spectroscopy
  • Discover ways in which water activity measurement and mathematical modelling can be used to evaluate the stability of freeze dried vaccines
  • Evaluate quality-by-design strategies, applied to spray drying, versus lyophilisation

Don't forget to check out the two-post conference interactive workshops taking place on 12th June.

For those looking to attend there are early-bird rates currently available of up to £400.

Further information is available at: www.pharmafreezedrying.com/wpn

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...